产品
编 号：F743396
产品类型
规格
价格
是否有货
结构图
CAS No: 1233953-61-1
产品详情
生物活性：
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.
体内研究：
Refanezumab (GSK249320; 10 mg/kg; 静脉给药; 在中风后 24 小时开始并每周继续给药 6 次) 显示神经评分和阶梯测试有更大的增加。Refanezumab 通过静脉注射后，可穿透病变部位，并且在中风后 24 小时对功能结果有轻微影响。Animal Model:Male Sprague Dawley rats (weight 361g)
Dosage:10 mg/kg
Administration:IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
Result:Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.
体内研究：
Refanezumab (GSK249320; 10 mg/kg; 静脉给药; 在中风后 24 小时开始并每周继续给药 6 次) 显示神经评分和阶梯测试有更大的增加。Refanezumab 通过静脉注射后，可穿透病变部位，并且在中风后 24 小时对功能结果有轻微影响。Animal Model:Male Sprague Dawley rats (weight 361g)
Dosage:10 mg/kg
Administration:IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
Result:Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备